Bottom-up reconstruction of a Synthetic Erythrocyte

SynEry aims to create a synthetic erythrocyte using advanced lipid vesicles and interdisciplinary methods to address global blood scarcity and safety challenges.

Subsidie
€ 3.685.549
2022

Projectdetails

Introduction

Blood is a precious and vital resource for many clinical interventions. Erythrocytes, its key component, are used to save thousands of lives every day worldwide. Yet, in low- and middle-income countries, its scarcity and unsafe control are endemic burdens that cost lives.

Background

In spite of several decades of attempts to develop a safe and universal blood substitute, this goal has yet to be achieved. Beyond the mere transport of gases, erythrocytes have evolved together with their host organisms to perform very specialized functions.

Complexity of Erythrocytes

It is now clear that much of their complexity is indispensable to establish effective cardiovascular regulation. Yet, reproducing this complexity in a synthetic, functional facsimile is a challenging endeavor that requires new methods and multidisciplinary approaches.

Goals of SynEry

The ambitious goal of SynEry is to reproduce, in an advanced lipid vesicle, the following key features of erythrocytes:

  1. Adequate lipid asymmetry with raft-like nanodomains
  2. Integration of essential functional proteins (both cytosolic and transmembrane) and a biomimetic cytoskeleton (conferring durability, flexibility, and biconcavity)
  3. Enhanced immune tolerability
  4. Responsivity to environmental cues (such as under deformation and hypoxia)

Interdisciplinary Consortium

These goals will be tackled by an interdisciplinary consortium bringing expertise on:

  • Droplet-based microfluidics combined with interfacial self-assembly of biofunctionalized nanoparticles (to build complex biomimetic membranes with ordered cytoskeletal nanodomains)
  • DNA origami and self-assembling peptide technologies (to reconstruct a biomimetic cell cortex)
  • In-vivo testing models (to verify biocompatibility and functionality)

Future Implications

The knowledge gained by producing a synthetic erythrocyte is envisioned to enable the production of artificial cells with in-vivo applicability and it will pave the way towards the future development of an effective blood substitute that can remedy pervasive global blood availability and safety issues.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 3.685.549
Totale projectbegroting€ 3.685.549

Tijdlijn

Startdatum1-4-2022
Einddatum31-3-2026
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • KATHOLIEKE UNIVERSITEIT LEUVENpenvoerder
  • FONDAZIONE CASA SOLLIEVO DELLA SOFFERENZA
  • AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
  • FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINE

Land(en)

BelgiumItalySpainFrancePortugal

Vergelijkbare projecten binnen EIC Pathfinder

EIC Pathfinder

Next Generation 3D Tissue Models: Bio-Hybrid Hierarchical Organoid-Synthetic Tissues (Bio-HhOST) Comprised of Live and Artificial Cells.

Bio-HhOST aims to create bio-hybrid materials with living and artificial cells for dynamic communication, enhancing tissue modeling and reducing animal use in drug research.

€ 1.225.468
EIC Pathfinder

Biomimetic Membranes for Organ Support

BioMembrOS aims to develop advanced biomimetic membranes for artificial respiration devices by mimicking the gas exchange structures of fish and birds to enhance efficiency and hemocompatibility.

€ 2.897.578
EIC Pathfinder

building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgans

THOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants.

€ 3.994.150
EIC Pathfinder

Blood as energy source to power smart cardiac devices

The BLOOD2POWER project aims to develop energy-harvesting vascular grafts using triboelectric nanogenerators to monitor performance and prevent failure through wireless data transmission.

€ 2.885.525
EIC Pathfinder

Exploiting ex vivo expansion and deep multiomics profiling to bring novel, efficient and safer hematopoietic stem cell gene therapies to clinical application

This project aims to innovate hematopoietic stem cell identification and engineering through advanced culture techniques and multiomics profiling, enhancing gene therapy for blood disorders and cancer.

€ 3.797.562

Vergelijkbare projecten uit andere regelingen

ERC Advanced...

Protein-regulated artificial cell populations and tissues

The PRO-ARTIS project aims to create interdependent artificial cell populations using a dynamic protein exchange platform to advance understanding of multicellular processes and integrate with living cells for biomedical applications.

€ 2.499.668
EIC Transition

Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactor

The project aims to upscale ex vivo production of universal platelets using innovative technologies to meet rising demand and ensure compatibility for patients with transfusion reactions.

€ 1.798.152
ERC Starting...

From engineering to evolution of synthetic cells with RNA origami

ENSYNC aims to create a self-replicating synthetic cell by evolving RNA origami structures within lipid vesicles through directed evolution and automation, enhancing insights into synthetic biology.

€ 1.749.624
ERC Consolid...

3D-assembly of interactive microgels to grow in vitro vascularized, structured, and beating human cardiac tissues in high-throughput

HEARTBEAT aims to create personalized, vascularized millimeter-scale heart tissues using innovative microgel assemblies to enhance stem cell interactions and mimic native environments.

€ 2.969.219
ERC Starting...

Artificial intelligence for synthetic functional genomics of blood

This project aims to develop predictive models of gene regulatory elements and networks using deep learning and single-cell genetic screens to enhance gene regulation in hematopoiesis.

€ 1.499.653